Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
32
NCNA Quote, Financials, Valuation and Earnings
Last price:
$1.18
Seasonality move
:
10.84%
Day range:
$1.17 - $1.26
52-week range:
$1.17 - $19.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.82x
Volume:
93.8K
Avg. volume:
110.1K
1-year change:
-81.02%
Market cap:
$4.7M
Revenue:
--
EPS (TTM):
-$14.84
Analysts' Opinion
-
Consensus RatingNuCana PLC has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $64.50, NuCana PLC has an estimated upside of 5230.58% from its current price of $1.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing -1966.12% downside risk from its current price of $1.21.
Fair Value
-
According to the consensus of 3 analysts, NuCana PLC has 5230.58% upside to fair value with a price target of $64.50 per share.
NCNA vs. S&P 500
-
Over the past 5 trading days, NuCana PLC has underperformed the S&P 500 by -5.98% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NuCana PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NuCana PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter NuCana PLC reported revenues of --.
Earnings Growth
-
NuCana PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NuCana PLC reported earnings per share of -$2.28.
Enterprise value:
-10.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$53.8M | -$45.9M | -$37.8M | -$11.2M | -$6.6M | |
| EBITDA | -$52.6M | -$45.3M | -$37.1M | -$11M | -$6.5M | |
| Diluted EPS | -$18.98 | -$20.33 | -$14.84 | -$4.12 | -$2.28 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $146.5M | $109.2M | $69.7M | $37.4M | $22.6M | |
| Total Assets | $154.2M | $120.6M | $76.7M | $41.4M | $26.1M | |
| Current Liabilities | $11.7M | $16.2M | $17.3M | $14.5M | $20.1M | |
| Total Liabilities | $12.4M | $16.6M | $17.8M | $14.9M | $20.3M | |
| Total Equity | $141.9M | $104M | $58.8M | $26.6M | $5.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33.1M | -$42.8M | -$14.7M | -$13.1M | -$6.3M | |
| Cash From Investing | -$674.6K | $3.8M | $77.9K | $3.4M | $25K | |
| Cash From Financing | -$323K | $9.2K | $7.8M | $80K | $6.1M | |
| Free Cash Flow | -$34.3M | -$43.4M | -$15.1M | -$13.2M | -$6.4M | |
NCNA
Sector
Market Cap
$4.7M
$43.9M
Price % of 52-Week High
6.23%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-81.02%
-29.11%
Beta (5-Year)
0.944
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.24
200-day SMA
Sell
Level
$3.52
Bollinger Bands (100)
Sell
Level
0.78 - 4.58
Chaikin Money Flow
Sell
Level
-118.2M
20-day SMA
Sell
Level
$1.27
Relative Strength Index (RSI14)
Sell
Level
34.53
ADX Line
Sell
Level
19.93
Williams %R
Buy
Level
-81.8182
50-day SMA
Sell
Level
$1.49
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
137M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Stock Forecast FAQ
In the current month, NCNA has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NCNA average analyst price target in the past 3 months is $64.50.
-
Where Will NuCana PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that NuCana PLC share price will rise to $64.50 per share over the next 12 months.
-
What Do Analysts Say About NuCana PLC?
Analysts are divided on their view about NuCana PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NuCana PLC is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is NuCana PLC's Price Target?
The price target for NuCana PLC over the next 1-year time period is forecast to be $64.50 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NCNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NuCana PLC is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NCNA?
You can purchase shares of NuCana PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NuCana PLC shares.
-
What Is The NuCana PLC Share Price Today?
NuCana PLC was last trading at $1.18 per share. This represents the most recent stock quote for NuCana PLC. Yesterday, NuCana PLC closed at $1.21 per share.
-
How To Buy NuCana PLC Stock Online?
In order to purchase NuCana PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
